|1.||Gotsadze, K: 2 articles (10/2007 - 04/2005)|
|2.||Wittig, Jo: 1 article (07/2013)|
|3.||Shah-Hosseini, Kija: 1 article (07/2013)|
|4.||Eichel, Andrea: 1 article (07/2013)|
|5.||Mösges, Ralph: 1 article (07/2013)|
|6.||Saalmüller, A: 1 article (12/2011)|
|7.||Haunschild, J: 1 article (12/2011)|
|8.||Rode, S: 1 article (12/2011)|
|9.||Glatthaar-Saalmüller, B: 1 article (12/2011)|
|10.||Rauchhaus, U: 1 article (12/2011)|
08/01/2011 - "Therefore the aim of the present study was to investigate whether patients with sinonasal disease would benefit in terms of olfactory function from oral treatment with a herbal drug (combination of primrose, gentian root, vervain, elder flowers, and sorrel: Sinupret(r)) which is commonly used in sinusitis. "
04/01/2006 - "Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis."
05/01/2005 - "The herbal medicinal product Sinupret has been successfully used for the treatment of sinusitis for 70 years. "
01/01/2001 - "[The administration of sinupret in the treatment of acute sinusitis in children]."
09/01/1980 - "[Treatment of chronic sinusitis with Sinupret]."
09/01/2001 - "Enhanced resistance to Sendai virus infection in DBA/2J mice with a botanical drug combination (Sinupret)."
10/20/1972 - "[Prevention of infection in the bronchitic syndrome by Sinupret]."
01/01/1999 - "In the case of Sinupret, a combination of 5 botanical drugs, the pharmacological profile was investigated thoroughly with respect to activities on secretion of the respiratory epithelium, with respect to anti-inflammatory activities and to effects against a murine Sendai-virus infection model (including in-vitro antiviral activities), after a randomised, placebo-controlled study of the ENT-clinic of the University of Freiburg had shown superiority of the verum in patients with chronic sinusitis. "
12/15/2011 - "Sinupret(®), a herbal medicinal product made from Gentian root, Primula flower, Elder flower, Sorrel herb, and Verbena herb is frequently used in the treatment of acute and chronic rhinosinusitis and respiratory viral infections such as common cold. "
11/06/1975 - "Sinupret is especially suitable for treatment after the acute phase of sinusitis during intervalls and as prophylaxis during the cold months with frequent infections of the upper respiratory tract."
07/01/2013 - "In this observational study, data on the efficacy, effects on quality of life and tolerability of the topical formulation SNS01 (Ectoin Rhinitis nasal spray) were compared to those of BNO-101 (Sinupret forte dragées) in patients with acute rhinosinusitis in the ear, nose, and throat (ENT) clinical setting. "
01/01/2009 - "[The use of sinupret in the combined treatment of acute otitis media in children]."
10/01/2007 - "The systemic inflammatory responses and the impact of sinupret therapy have been investigated in 14 patients with acute otitis media, AOM. "
10/01/2007 - "Systemic inflammatory responses in patients with acute otitis media and the impact of treatment with sinupret."
04/01/2007 - "To treat seros otitis media Sinupret was used as a monotherapy drug. "
04/01/2007 - "In treatment of acute otitis media and sinusitis Sinupret is recommended in the third period of disease in combination with antibiotics."
|5.||Paramyxoviridae Infections (Parainfluenza)
09/01/2001 - "It was investigated whether the botanical drug combination Sinupret is able to modulate the resistance of mice to a respiratory tract infection with Sendai virus (Parainfluenza viridae) if given prophylactically to the animals. "
12/15/2011 - "Therefore experiments have been performed to measure the antiviral activity of Sinupret(®) oral drops (hereinafter referred to as "oral drops") and Sinupret(®) dry extract (hereinafter referred to as "dry extract"), in vitro against a broad panel of both enveloped and non-enveloped human pathogenic RNA and DNA viruses known to cause infections of the upper respiratory tract: influenza A, Chile 1/83 (H1N1) virus (FluA), Porcine Influenza A/California/07/2009 (H1N1) virus (pFluA), parainfluenza type 3 virus (Para 3), respiratory syncytial virus, strain Long (RSV), human rhinovirus B subtype 14 (HRV 14), coxsackievirus subtype A9 (CA9), and adenovirus C subtype 5 (Adeno 5). "
|1.||Anti-Bacterial Agents (Antibiotics)
|2.||Nasal Decongestants (Decongestants)
|3.||RNA (Ribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)